TLDR Most patients experienced significant but reversible hair loss during treatment.
The study retrospectively evaluated alopecia in 470 patients treated with a paclitaxel and platinum combination for various gynecological cancers from 1993 to 2006. Patients received 6 cycles of chemotherapy with either paclitaxel and carboplatin or paclitaxel and cisplatin. Grade 3 alopecia was observed in 91.7% of patients, with no cases of grade 4 alopecia. The severity and frequency of alopecia were similar between the two chemotherapy combinations. Alopecia became more pronounced with additional chemotherapy cycles but was reversible after treatment concluded.
97 citations,
September 2006 in “Pharmaceutical Research” No treatment fully prevents hair loss from chemotherapy yet.
February 2021 in “Research Square (Research Square)” The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.
21 citations,
August 2003 in “Seminars in oncology nursing” Nurses are crucial in managing chemotherapy side effects for ovarian cancer patients to improve their quality of life.
29 citations,
August 2007 in “Annals of Oncology” Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.
12 citations,
March 2016 in “Life Sciences” The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.
March 2018 in “International journal of basic and clinical pharmacology” Carboplatin-paclitaxel is preferred for advanced lung cancer due to its balance of affordability and patient well-being.
